Literature DB >> 2071229

Trisomy 12 and K-ras-2 amplification in human ovarian tumors.

T L Yang-Feng1, S B Li, W Y Leung, M L Carcangiu, P E Schwartz.   

Abstract

Cytogenetic analysis was performed on 11 benign and borderline ovarian tumors. Trisomy 12, identified as a sole abnormality in 6 tumors, is likely a specific karyotypic change in different benign and borderline tumors and may well be a primary chromosomal lesion in these tumors. The possible association between amplification of the proto-oncogene K-ras-2 which is located on chromosome 12 and trisomy 12 was investigated. DNA blotting analysis of 64 tumors indicates that trisomy 12 does not seem to be related to K-ras-2 amplification in ovarian tumors. K-ras-2 amplification was observed in 3 high-grade tumors from 3 patients with metastases.

Entities:  

Mesh：

Year:  1991        PMID： 2071229     DOI： 10.1002/ijc.2910480508

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  9 in total

1.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.

Authors:  Daniela Matei; Michael W Sill; Heather A Lankes; Koen DeGeest; Robert E Bristow; David Mutch; S Diane Yamada; David Cohn; Valerie Calvert; John Farley; Emanuel F Petricoin; Michael J Birrer
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

2.  Genomic aberrations in borderline ovarian tumors.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; Ben Davidson; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

3.  Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features.

Authors:  B C Bastian; P E LeBoit; D Pinkel
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

4.  Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components.

Authors:  N G Wolf; F W Abdul-Karim; N J Schork; S Schwartz
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

5.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

6.  Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.

Authors:  D L Persons; L C Hartmann; J F Herath; T J Borell; W A Cliby; G L Keeney; R B Jenkins
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

7.  Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Authors:  Ashley H Birch; Suzanna L Arcand; Kathleen K Oros; Kurosh Rahimi; A Kevin Watters; Diane Provencher; Celia M Greenwood; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

8.  Targeting KRAS Regulation with PolyPurine Reverse Hoogsteen Oligonucleotides.

Authors:  Alexandra Maria Psaras; Simonas Valiuska; Véronique Noé; Carlos J Ciudad; Tracy A Brooks
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

Review 9.  Metabolic Reprogramming of Immune Cells at the Maternal-Fetal Interface and the Development of Techniques for Immunometabolism.

Authors:  Yiqiu Wei; Jinli Ding; Jianan Li; Songchen Cai; Su Liu; Ling Hong; Tailang Yin; Yan Zhang; Lianghui Diao
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.